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Protein tyrosine phosphatase Shp2 
deficiency in podocytes attenuates 
lipopolysaccharide-induced 
proteinuria
Ming-Fo Hsu1, Ahmed Bettaieb1,5, Yoshihiro Ito1, James Graham1,2, Peter J. Havel1,2 & Fawaz 
G. Haj1,3,4
Podocytes are specialized epithelial cells that play a significant role in maintaining the integrity of the 
glomerular filtration barrier and preventing urinary protein leakage. We investigated the contribution 
of protein tyrosine phosphatase Shp2 to lipopolysaccharide (LPS)-induced renal injury. We report 
increased Shp2 expression in murine kidneys and cultured podocytes following an LPS challenge. To 
determine the role of podocyte Shp2 in vivo, we generated podocyte-specific Shp2 knockout (pod-
Shp2 KO) mice. Following administration of LPS, pod-Shp2 KO mice exhibited lower proteinuria and 
blood urea nitrogen concentrations than controls indicative of preserved filter integrity. In addition, 
renal mRNA and serum concentrations of inflammatory cytokines IL-1β, TNFα, INFγ and IL-12 p70 
were significantly decreased in LPS-treated knockout mice compared with controls. Moreover, the 
protective effects of podocyte Shp2 deficiency were associated with decreased LPS-induced NF-κB and 
MAPK activation, nephrin phosphorylation and attenuated endoplasmic reticulum stress. These effects 
were recapitulated in differentiated E11 murine podocytes with lentiviral-mediated Shp2 knockdown. 
Furthermore, Shp2 deficient podocytes displayed reduced LPS-induced migration in a wound healing 
assay. These findings identify Shp2 in podocytes as a significant contributor to the signaling events 
following LPS challenge and suggest that inhibition of Shp2 in podocytes may present a potential 
therapeutic target for podocytopathies.
The glomerulus is the basic filtration unit of the kidney that prevents macro-molecules from being lost into the 
urine, and an effective glomerular filtration barrier (GFB) is critical for normal renal function1. Structurally the 
GFB is composed of podocytes, glomerular basement membrane, and endothelium. Podocytes are differentiated 
cells with extended membrane branches termed foot processes that interdigitate together to form unique inter-
cellular junctions called slit diaphragms. Foot processes flattening damages filtration barrier integrity and corre-
lates with development of proteinuria in humans and animal models of podocyte injury2. Proteinuria is an early 
marker of renal injury and may accelerate disease progression towards renal failure3. Therefore, understanding 
the intricate signaling mechanisms underlying podocyte dysfunction is essential for developing effective therapies 
for proteinuria.
Protein tyrosine phosphorylation and dephosphorylation are fundamental signaling mechanisms that con-
tribute to both normal podocyte function and repair after injury4. Changes in phosphotyrosine-based signaling 
are mediated by the dynamic and opposing actions of protein tyrosine kinases and protein tyrosine phosphatases 
(PTPs)5. A growing body of evidence suggests a role for PTPs in podocyte function and repair. Biochemical 
studies in vitro and rodent models implicate protein tyrosine phosphatase 1B (PTP1B) in podocyte function. 
PTP1B inhibition attenuates complement-mediated glomerular injury6 and protects against podocyte injury 
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and proteinuria7. Also, PTP1B can regulate podocyte function through tyrosine phosphorylation of nephrin, 
a key podocyte protein that regulates actin cytoskeleton8. Moreover, expression of the Src homology 2 (SH2) 
domain-containing phosphatase 1 (Shp1) increases in podocytes after hyperglycemia leading to decreased 
nephrin tyrosine phosphorylation9. Together, these studies establish a role for some PTPs in podocyte function, 
but additional investigation into the contribution of these enzymes to podocytopathies is warranted.
Src homology 2 domain-containing phosphatase 2 (Shp2; encoded by PTPN11) is a ubiquitously expressed 
non-transmembrane phosphatase. Shp2 contains two N-terminal SH2 domains, a tyrosine phosphatase domain, 
and a C-terminal region with phosphorylation sites10. The SH2 domains target Shp2 to specific phosphotyros-
ine proteins, including some receptor tyrosine kinases (RTKs) and several scaffolding adaptors11. Shp2 plays 
an essential role in most RTK signaling pathways, where it is required for normal activation of the extracellular 
signal-regulated kinase (ERK) pathway, and its downstream transcriptional targets12, 13. Accordingly, Shp2 plays 
a significant role in maintaining homeostasis by regulating many facets of cell signaling. Recent studies establish 
an association of Shp2 with nephrin and demonstrate that podocytes lacking Shp2 do not develop foot process 
spreading after injury in vivo using protamine sulfate or nephrotoxic serum models14. In this study, we deter-
mined the contribution of Shp2 in podocytes to LPS-induced podocyte injury and investigated the underlying 
mechanisms.
Results
Increased renal and podocyte Shp2 expression upon LPS treatment. Shp2 is differentially 
expressed in various types of renal tumors15, but its expression in normal kidneys and podocytes remains largely 
unexplored. Recently, Verma et al. report increased Shp2 phosphorylation at Tyr542, a putative marker of enzyme 
activity, in a subset of human glomerular diseases14. We investigated renal Shp2 transcript and protein expression 
in LPS-treated wild-type mice as detailed in methods. Immunoblots of total kidney lysates revealed a significant 
increase in Shp2 at both transcript and protein levels upon LPS treatment (Fig. 1a). Similarly, co-immunostaining 
of Shp2 and synaptopodin demonstrated LPS-induced increase in Shp2 expression in podocytes (Fig. 1b). Also, 
Shp2 expression was determined in differentiated E11 murine podocytes treated with LPS for 6, 12 and 24 hours. 
Immunoblotting revealed a time-dependent, LPS-induced increase in Shp2 protein expression, concomitant with 
decreased synaptopodin expression as previously reported16 (Fig. 1c). Thus, Shp2 expression is modulated in 
kidneys and podocytes upon LPS challenge.
Mice with podocyte Shp2 deficiency are resistant to LPS-induced injury. Upregulation of renal 
Shp2 expression upon LPS challenge led us to hypothesize that Shp2 may play a role in signaling events following 
LPS-induced podocyte injury. To that end, we generated mice with podocyte-specific Shp2 deletion as detailed 
in methods. Podocyte Shp2 knockout mice (hereafter termed pod-Shp2 KO) appeared healthy and with no gross 
defects in the kidneys. Deletion of Shp2 was confirmed using PCR, biochemical and immuno-histochemical 
approaches. The recombined Shp2 product was detected only in kidneys of pod-Shp2 KO mice (Fig. 2a). In addi-
tion, immunoblots of primary podocytes from control and pod-Shp2 KO mice demonstrated ablation of Shp2 in 
knockout mice (Fig. 2b). Shp2 expression was comparable in other tissues (adipose, liver, and muscle) of control 
and knockout mice suggesting specificity of deletion. Moreover, immunostaining of Shp2 and synaptopodin in 
kidney sections of control and pod-Shp2 KO mice further demonstrated deletion of Shp2 in podocytes of knock-
out mice (Fig. 2c). Collectively, these data demonstrate efficient and specific deletion of Shp2 in podocytes and 
establish pod-Shp2 KO mice as a suitable model to investigate the potential contribution of Shp2 to LPS-induced 
renal injury.
To evaluate the effects of podocyte Shp2 deficiency on renal injury, age-matched control, and pod-Shp2 KO 
male mice were treated with LPS and sacrificed after 24 hours (Fig. 3a). LPS led to a comparable mild reduction in 
body weight of control and knockout mice (Fig. 3b). However, LPS-induced increase in kidney weights was sig-
nificantly higher in control compared with knockout mice (Fig. 3c,d). Notably, LPS induced a significant increase 
in total urinary proteins, but that was lower in knockout mice than controls indicative of preserved filter integrity 
and renal function (Fig. 3e). Consistent with these observations, LPS-induced increase in blood urea nitrogen 
was significantly lower in knockout mice compared with controls (Fig. 3f). Similar findings were obtained using 
female mice establishing that the effects of podocyte Shp2 deletion on the LPS-induced injury were not gender 
specific (Fig. S1). Moreover, the nephrotoxic nephritis model of renal injury also demonstrated protective effects 
of podocyte Shp2 deficiency as evidenced by lower urine albumin/creatinine and blood urea nitrogen in knock-
out mice than controls (Fig. S2). Together, these data establish protective effects of podocyte Shp2 deficiency 
against LPS-induced renal dysfunction.
Decreased systemic and renal inflammation in pod-Shp2 KO mice after LPS challenge. LPS 
treatment increases systemic and renal inflammatory cytokines in rodent models17, 18. We evaluated the effects of 
podocyte Shp2 deficiency on LPS-induced circulating and renal inflammatory cytokines. Consistent with pub-
lished reports17, 19, interleukin-1b (Il-1b), interleukin-6 (Il-6) and tumor necrosis factor alpha (Tnfa) renal mRNA, 
as well as IL-1β, TNFα, interferon-γ (INFγ) and interleukin-12 (IL-12) p70 serum concentrations were signifi-
cantly increased in LPS-treated mice (Fig. 4a,b). However, LPS-induced increase of inflammatory cytokines was 
significantly less in pod-Shp2 KO mice compared with controls. Similar attenuation of inflammatory markers was 
also observed in female knockout mice (Fig. S3).
LPS is primarily recognized by toll-like receptor 4 (TLR4)20, 21. Through TLR4 activation the nuclear 
factor-kappa B (NF-κB) and MAPK (such as JNK and p38) pathways are significant effectors for cytokine pro-
duction and LPS-induced inflammation22. Accordingly, activation of NF-κB, JNK and p38 was determined in 
kidneys of control and knockout mice under basal and LPS-treated conditions. LPS treatment induced a signifi-
cant increase in NF-κB, JNK and p38 phosphorylation in control mice but that was significantly less in pod-Shp2 
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KO mice (Fig. 4c). In addition, endoplasmic reticulum (ER) stress is implicated in the pathogenesis of proteinuric 
kidney diseases in experimental models of renal pathophysiology and human kidney23, 24. Eukaryotic translation 
initiation factor (eIF2α) phosphorylation and spliced XBP1 (sXBP1) expression were decreased in LPS-treated 
pod-Shp2 KO mice compared with controls indicative of decreased ER stress (Fig. 4c). We further investigated 
phosphorylation of Shp2 Tyr542 (a marker of enzymatic activity) and nephrin under basal and LPS-treated states. 
LPS induced a significant increase in Shp2 and nephrin tyrosine phosphorylation in control mice, but these were 
significantly reduced in pod-Shp2 KO mice (Fig. 5a,b). Collectively, these findings are in keeping with the attenu-
ated renal and systemic inflammatory markers as well as podocyte injury in LPS-treated knockout mice.
Shp2 deficiency in E11 podocytes attenuates LPS-induced inflammatory response. The renal 
inflammatory response to LPS-induced injury encompasses many cells including proximal tubules and glomer-
ular cells (podocytes, macrophages, endothelia and mesangial). Since podocytes contribute to LPS-induced 
response25 we generated E11 podocyte cell lines with Shp2 knockdown (KD) and rescue (KD-R) to delineate 
the contribution of Shp2 in podocytes to LPS-induced response. Differentiated KD and KD-R podocytes were 
stimulated with LPS, and the effects of Shp2 deficiency on LPS-induced inflammatory response were deter-
mined. Consistent with findings in kidneys, LPS treatment increased NF-κB, JNK and p38 phosphorylation 
Figure 1. LPS treatment increases renal and podocyte Shp2 expression. (a) Immunoblots of Shp2 and tubulin 
in total kidney lysates. Control (saline, n = 6) and LPS-injected (n = 6) wild-type male mice were sacrificed 
24 hours after injection. Representative images are shown and each lane represents an animal. Shp2 protein 
expression (left, normalized to tubulin) and mRNA (right, normalized to Tbp) presented in bar charts as 
means + SEM. *p < 0.05 indicates a significant difference between saline and LPS-treated mice. (b) Co-
immunostaining of Shp2 (green) and synaptopodin (Synpo, red) in kidney sections from saline and LPS-treated 
wild-type mice. Scale bar: 20 µm. (c) Differentiated E11 podocytes were treated with PBS for 24 hours and 
with LPS for 6, 12 and 24 hours. Cell lysates were immunoblotted for Shp2, synaptopodin, and actin. Protein 
expression was normalized to actin and presented in a bar chart as means + SEM from three independent 
experiments. *p < 0.05 and #p < 0.05 indicate a significant difference between PBS (24 h) and LPS-treated 
groups for Shp2 and synaptopodin, respectively. A.U., arbitrary units.
www.nature.com/scientificreports/
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and Caspase3 cleavage and these were significantly lower in Shp2 knockdown than rescued podocytes (Fig. 6a). 
Moreover, Shp2 knockdown podocytes exhibited attenuated LPS-induced ER stress as evidenced by decreased 
phosphorylation of pancreatic ER kinase (PERK), eIF2α, inositol-requiring enzyme 1α (IRE1α) and lower sXBP1 
expression (Fig. 6b). Furthermore, LPS-induced tyrosine phosphorylation of Shp2 and nephrin were significantly 
lower in Shp2 knockdown compared with rescued podocytes (Fig. 6c). These findings establish that podocytes 
contribute to the protective effects of Shp2 deficiency against LPS-induced injury.
Shp2 deficiency reduces LPS-induced podocyte migration. Podocytes are terminally differenti-
ated cells with low migration ability at physiological state. LPS-induced podocyte motility has been implicated 
in the pathophysiology of renal injury26. In addition, Shp2 plays a role in the regulation of cell migration27–30. 
Accordingly, we determined the effects of Shp2 deficiency on LPS-induced podocyte migration using wound 
healing assay as detailed in methods. At basal state (saline-treated) Shp2 knockdown podocytes exhibited less 
motility than rescued cells (Fig. 7a,b). Also, LPS treatment further enhanced podocyte migration; however Shp2 
knockdown significantly decreased the number of podocytes migrating into the wound (Fig. 7a,b). These findings 
demonstrate that Shp2 deficient podocytes exhibit lower migration in response to LPS and are consistent with the 
protective effects of Shp2 podocyte deficiency in vivo.
Discussion
Podocyte injury and dysfunction are significant contributors to the pathogenesis of proteinuria and glomerulo-
sclerosis. Thus, deciphering the intricate molecular and signaling mechanisms that are implicated in podocyte 
dysfunction is paramount for developing therapeutic modalities for proteinuria. In the current study, we inves-
tigated the contribution of Shp2 in podocytes to LPS-induced injury. We report increased Shp2 expression in 
murine kidneys and podocytes following an LPS challenge. Importantly, podocyte-specific Shp2 ablation atten-
uated LPS-induced renal dysfunction. The protective effects of podocyte Shp2 deficiency were associated with 
decreased renal and systemic inflammatory response in vivo and were recapitulated in Shp2 deficient murine E11 
podocytes. Together, these findings identify Shp2 in podocytes as a significant contributor to the signaling events 
following LPS challenge.
Shp2 expression increased in murine kidneys and cultured podocytes following LPS treatment. The mech-
anism underlying upregulation in Shp2 expression and if it translates to increased enzyme activity remain to 
be elucidated. However, these findings are in line with increased Shp2 expression and activity in states that are 
associated with elevated inflammation such as insulin resistance and high-fat diet-induced obesity31, 32. Also, Shp2 
expression is increased in murine podocytes after puromycin-induced injury33. Moreover, Verma et al. report 
increased Shp2 tyrosine phosphorylation, and possibly activity, in mouse kidneys after protamine sulfate-induced 
Figure 2. Efficient and specific deletion of Shp2 in podocytes. (a) Genomic DNA was extracted from tissues 
(as indicated) of control (Ctrl) and pod-Shp2 knockout (KO) mice. Deletion of the floxed allele was detected by 
PCR, and GAPDH served as a loading control. (b) Immunoblots of Shp2 protein expression in isolated primary 
podocytes, adipose (epididymal fat), liver and muscle from Ctrl and KO mice. Tubulin and synaptopodin 
(Synpo, for podocytes) presented as loading controls. (c) Immunostaining of Shp2 (green) and synaptopodin 
(red) in kidney sections from Ctrl and KO mice. Scale bar: 50 µm.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 461  | DOI:10.1038/s41598-017-00564-3
injury and in a subset of human glomerular diseases (minimal change nephrosis and membranous nephropathy 
but not in focal segmental glomerulosclerosis)14. Shp2 activity was indirectly assessed through Tyr542 phospho-
rylation (a putative marker of increased activity since phosphorylation at this residue relieves basal inhibition)14, 34. 
In line with these findings, we observed increased Shp2 Tyr542 phosphorylation in kidneys and podocytes upon 
LPS challenge. It is worth noting that increased Shp2 activity during glomerular disease pathogenesis may be cor-
relative and does not necessarily demonstrate causation. However, if causation is established then Shp2 podocyte 
inhibition may be of potential value in combating podocytopathies.
Figure 3. Pod-Shp2 KO mice are more resistant than controls to LPS-induced renal injury. (a) Schematic of 
experimental timeline for LPS administration and mice sacrifice. Body weight (b), kidney weight (c), kidney/
body weight ratio (d), urinary proteins concentration (e) and blood urea nitrogen (f) of control (Ctrl, n = 8) 
and pod-Shp2 knockout (KO, n = 8) mice without (saline) and with LPS treatment. *p < 0.05 and **p < 0.01 
indicate a significant difference between saline and LPS treatments; †p < 0.05 and ††p < 0.01 indicate a significant 
difference between Ctrl and KO mice. Data were presented as means + SEM. A.U., arbitrary units.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 461  | DOI:10.1038/s41598-017-00564-3
Figure 4. Attenuated LPS-induced inflammatory response in pod-Shp2 KO mice. Renal mRNA of Il-1b, Il-6 
and Tnfa (a), and plasma concentrations of IL-1β, TNFα, INFγ and IL-12 p70 (b) in saline and LPS-treated 
control (Ctrl, n = 6) and pod-Shp2 knockout (KO, n = 6) mice. (c) Kidney lysates from Ctrl and KO mice 
without (saline) and with LPS treatment were immunoblotted for phosphorylated NF-κB p65, JNK, p38, 
peIF2α and their respective proteins, spliced XBP1 (sXBP1), and actin as a loading control. Representative 
images are shown. Bar charts represent pNF-κB p65/NF-κB p65, pJNK/JNK, pp38/p38, peIF2α/eIF2α and 
sXBP1/actin as means + SEM. For all bar charts, *p < 0.05 and **p < 0.01 indicate a significant difference 
between saline and LPS treatments; †p < 0.05 and ††p < 0.01 indicate a significant difference between Ctrl and 
KO mice. A.U., arbitrary units.
www.nature.com/scientificreports/
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Shp2 ablation in podocytes attenuated LPS-induced renal dysfunction as evidenced by decreased proteinuria 
and blood urea nitrogen, two biomarkers of renal function. In addition, the protective effects of podocyte Shp2 
deficiency were comparable in male and female mice indicating that they were not gender specific. Moreover, 
these effects were also observed using the nephrotoxic nephritis model demonstrating that they were not unique 
to a particular challenge. In this experimental platform Shp2 deficiency likely did not impact normal podocyte 
development due to delayed Shp2 deletion after podocyte maturation (when podocin-driven Cre recombinase is 
expressed35). Notably, the protective effects of Shp2 deletion in vivo were recapitulated in murine E11 podocytes 
with lentiviral-mediated Shp2 knockdown consistent with being cell autonomous. However, we cannot rule out 
direct or indirect effects of podocyte Shp2 deletion in vivo on other cell types/tissues that are implicated in LPS 
inflammatory response. Nevertheless, the current findings are consistent with the protective effects of podocyte 
Shp2 deficiency and pharmacological inhibition in vivo against protamine sulfate or nephrotoxic serum14. In total, 
the aforementioned studies establish that podocyte Shp2 deficiency and pharmacological inhibition attenuate 
renal injury after an acute challenge. It would be of considerable interest to further delineate the potential contri-
bution of Shp2 in podocytes, if any, to chronic kidney diseases.
Podocyte Shp2 deficiency in vivo and culture attenuated LPS-induced NF-κB inflammatory response and 
MAPK signaling. A growing body of evidence implicates activation of NF-κB36 and MAPK37 pathways in renal 
inflammation and injury. Activated NF-κB in podocytes induces pro-inflammatory chemokines and aggravates 
proteinuria in experimental glomerulonephritis in mice38. Therefore, the protective effects of podocyte Shp2 
deficiency against LPS may be mediated, at least partly, by decreased activation of NF-κB and MAPK pathways. 
The mechanism by which Shp2 deficiency attenuates MAPK and NF-κB signaling is unclear but may be related 
to overall reduction in inflammation. Of note, the NF-κB essential modulator NEMO regulates proinflamma-
tory signaling through NF-κB in podocytes39. In addition, NEMO modulates ERK activation to enhance podo-
cyte migration in an NF-κB independent manner40. Shp2 is also required for normal activation of ERK in most 
RTK signaling pathways, and it is interesting to speculate on interactions between Shp2 and NEMO cascades 
to regulate signaling during podocyte injury. Shp2 may serve as a positive14, 41, 42 or negative43, 44 regulator of 
the inflammatory response and is likely to act in a cell-type and tissue-/stimulus-dependent manner to elicit 
anti- and pro-inflammatory responses. Moreover, podocyte Shp2 deficiency affected other signaling pathways 
that are implicated in podocyte injury, in particular, ER stress. ER stress contributes to podocyte injury in rat 
Figure 5. Attenuated LPS-induced Shp2 and nephrin phosphorylation in pod-Shp2 KO mice. (a) Kidney 
lysates from control (Ctrl) and pod-Shp2 knockout (KO) mice without (saline) and with LPS treatment were 
immunoblotted for pShp2 (Tyr542), Shp2 and actin as a loading control. Representative images are shown and 
each lane represents an animal. Bar chart represents pShp2 (Tyr542)/actin as means + SEM (n = 6). *p < 0.05 
indicates a significant difference between saline and LPS treatments; †p < 0.05 indicates a significant difference 
between Ctrl and KO mice. A.U., arbitrary units. (b) Immunostaining of pNephrin (Y1176/Y1193) in kidney 
sections from Ctrl and KO mice without (saline) and with LPS treatment. Lower panel includes enlarged images 
that are highlighted by white boxes in the upper panel. Scale bar: 50 µm.
www.nature.com/scientificreports/
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Figure 6. Shp2 deficiency in E11 podocytes attenuates LPS-induced inflammatory response and ER stress. 
Differentiated podocytes with Shp2 knockdown (KD) and rescue (KD-R) were treated with PBS and with LPS 
for 24 hours. Cell lysates were subjected to immunoblots with primary antibodies as indicated. Representative 
images are shown. Bar charts of pNF-κB p65/NF-κB p65, pJNK/JNK, pp38/p38, cleaved Caspase3/tubulin (a), 
pPERK/PERK, peIF2α/eIF2α, pIRE1α/IRE1α and sXBP1/tubulin (b), pNephrin/Nephrin and pShp2/tubulin 
(c) are presented as means + SEM from three independent experiments. *p < 0.05 and **p < 0.01 indicate a 
significant difference between PBS and LPS treatments; †p < 0.05 and ††p < 0.01 indicate a significant difference 
between KD-R and KD podocytes. A.U., arbitrary units.
www.nature.com/scientificreports/
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primary podocytes45 and mouse immortalized podocytes46. Further, a recent study highlights the role of ER 
stress-derived proteinuria in the progression of human chronic kidney disease3. The attenuated ER stress in Shp2 
deficient podocytes is consistent with the reported decrease in ER stress upon hepatic Shp2 deficiency32, and in 
line with the renal protective effects of Shp2 podocyte deficiency. While our findings provide insights into the 
signaling mechanisms that are associated with Shp2 deficiency following LPS injury they do not identify the 
target(s) that mediate Shp2 actions in podocytes. Shp2 associates with and enhances tyrosine phosphorylation 
of the slit diaphragm protein nephrin14, which is also regulated by Shp19 and PTP1B7, 8 in podocytes. In line with 
these observations, we demonstrated increased nephrin phosphorylation concomitant with elevated Shp2 tyros-
ine phosphorylation upon LPS challenge, suggesting that nephrin may be a component of the signaling cascade 
that mediates Shp2 action upon LPS-induced renal injury. Also, regulatory proteins for cell-matrix interactions 
such as focal adhesion kinase and urokinase receptor promote cell migration, and their podocyte deficiency pro-
tects against LPS-induced proteinuria26, 47. Shp2 activity positively regulates the activation of focal adhesion and 
integrin complex29, 48–50. Consistent with these observations, Shp2 deficient E11 podocytes exhibited decreased 
migration in wound healing after LPS challenge. Additional studies are needed to delineate the molecular sign-
aling mechanisms mediating Shp2 actions in podocytes, but the current findings suggest that Shp2 inhibition in 
podocytes may be of potential therapeutic value for podocytopathies.
Figure 7. Decreased LPS-induced cell migration in Shp2 deficient podocytes. (a) Differentiated E11 podocytes 
with Shp2 knockdown (KD) and rescue (KD-R) were cultured with PBS and LPS for 48 hours after wound 
induction. Images were acquired before treatment (0 h) and at 24 and 48 h post wound. Scale bar: 200 µm. 
Cell numbers in the wound track were counted and presented in the bar chart (b) as means + SEM from four 
independent experiments. *p < 0.05 and **p < 0.01 indicate a significant difference between PBS and LPS 
treatments; ††p < 0.01 indicates a significant difference between KD-R and KD podocytes.
www.nature.com/scientificreports/
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As an essential regulator of various RTK signaling pathways, Shp2 was reported as oncogenic tyrosine phos-
phatase51. Also activating Shp2 mutants have been studied in association with developmental disorders such 
as Noonan syndrome52 and are found in several human cancers53. Accordingly, several Shp2 pharmacological 
inhibitors are being developed for cancer therapy54 including a promising allosteric inhibitor that exhibits high 
specificity and capacity to suppress proliferation in RTK-driven human cancer cells and mouse tumor xenograft 
models55. Previous14 and current studies establish protective effects of podocyte Shp2 deficiency against acute 
renal injury raising the possibility of utilizing Shp2 pharmacological inhibitors to combat podocytopathies.
Materials and Methods
Mouse studies. Shp2 floxed (Shp2fl/fl) mice on a mixed 129Sv/J × C57Bl/6J background were generated 
and described previously56. Transgenic mice expressing Cre recombinase under control of podocin-specific 
promoter NPHS2 on the C57Bl/6J background were purchased from Jackson laboratories. Shp2fl/fl were bred 
to podocin-Cre to generate mice lacking Shp2 in podocytes (pod-Shp2 KO). DNA extracted from tails was 
used for genotyping of the Shp2 floxed allele and for the presence of Cre by polymerase chain reaction (PCR). 
Primers used to check for germline deletion were: forward 5′-TAGCTGCTTTAACCCTCTGTGT and reverse 
5′-AATTGCGGCTTCTTGTCCT. All mice studied were age-matched and were maintained on a 12 h light-dark 
cycle, with free access to water and standard laboratory chow (Purina lab chow, # 5001). For lipopolysaccharide 
(LPS)-induced proteinuria, 10–12 weeks old control and pod-Shp2 knockout mice received a single intraperito-
neal injection of LPS (Sigma, from Escherichia coli 0111:B4; 16 µg/g body weight) in 0.9% sterile saline solution17. 
Mice were sacrificed 24 h after injection of LPS and kidneys were harvested and processed for biochemical and 
histological analyses. Urine and blood samples were collected one hour before and at sacrifice, respectively. For 
the nephrotoxic nephritis model, 10–12 weeks old control and pod-Shp2 KO mice were injected retro-orbitally 
with sheep anti-rat glomerular serum (Probetex, 5 µl/g body weight) or saline. Urine samples were collected at 24 
and 48 h, and blood samples were collected at 48 h post injection. All the mouse studies were conducted according 
to federal guidelines and were approved by the Institutional Animal Care and Use Committee at the University 
of California-Davis.
Metabolic measurements. Urinary protein was determined by Bradford method using Protein Assay Dye 
Reagent Concentrate solution (Bio-Rad). Albumin and creatinine concentrations were measured using corre-
sponding kits that were purchased from Sigma. Blood plasma samples were collected in EDTA-treated tubes by 
centrifugation at 2,000× g for 20 minutes to deplete platelets, and inflammation-related biomarkers were assayed 
using the V-PLEX kit (Meso Scale Discovery). In addition, blood urea nitrogen was measured using urea assay kit 
(Sigma). All procedures were performed according to manufacturer instructions.
Immunohistochemistry. Kidney samples from control and pod-Shp2 knockout mice were fixed in 4% par-
aformaldehyde, embedded in paraffin and deparaffinized in xylene. Sections were stained using synaptopodin, 
Shp2 (Santa Cruz) and pNephrin (Tyr1176/Tyr1193) antibodies at 4 °C overnight. Detection was performed with 
appropriate Alexa Fluor-conjugated secondary antibodies (Thermo Fisher Scientific) and then visualized using 
Olympus BX51 microscope (Fig. 2c) or Olympus FV1000 Laser Scanning Confocal microscope (Figs 1b and 5b).
Podocyte isolation. Podocytes were isolated from control and pod-Shp2 knockout mice using established 
protocols57, 58 with some modifications. Briefly, kidneys were decapsulated and minced in Krebs-Henseleit saline 
(119 mM NaCl, 4.7 mM KCl, 1.9 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4 and 25 mM NaHCO3, pH 7.4). 
Samples were pooled and filtered through sieves in order of 250, 100 and 40 µm. The fraction trapped on 40 µm 
sieve containing glomeruli was washed and collected, then digested in Hanks buffer supplemented with 0.1% col-
lagenase D (Roche) and 0.25% trypsin (Gibco) for 30 min at 37 °C. Solutions were filtered through a 40 µm sieve 
and podocytes centrifuged at 1500 × g for 5 minutes. Cell pellets were lysed using radio-immunoprecipitation 
assay (RIPA) buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% SDS, 5 mM EDTA, 20 mM NaF, 
10 mM Na4P2O7, 1% Triton X-100, 1% sodium deoxycholate and protease inhibitors.
Cell culture. E11 murine kidney podocyte cell line was purchased from Cell Lines Service (Eppelheim, 
Germany). E11 podocytes are proliferative when maintained at 33 °C in RPMI 1640 medium supplemented with 
10% fetal bovine serum (FBS). To induce differentiation, E11 cells were cultured at 37 °C for two weeks. Shp2 
silencing was achieved by testing five individual hairpin shRNAs (GE Healthcare Dharmacon) through lentiviral 
infection. Lentiviruses were produced by co-transfection of packaging (psPAX2) and envelope (pMD2.G) vectors 
(Addgene) in HEK293FT cells using Lipofectamine 2000 (Invitrogen) following the manufacturer’s guidelines. 
Infected E11 podocytes were selected by puromycin (2 µg/ml) to generate stable colonies. E11 cells with Shp2 
knockdown (KD) were rescued (KD-R) with Shp2 by transfection with pCMV human Shp2 wild type (Addgene), 
and stable cell lines were generated by neomycin (G418, 400 µg/ml) selection. For biochemical studies differen-
tiated KD and KD-R podocytes were starved for 24 h then stimulated with LPS (10 μg/ml) for indicated times. 
For wound healing assays differentiated KD and KD-R podocytes were starved for 24 h then wound was gen-
erated using 200 μl pipette tip. Cells were incubated in RPMI medium (10% FBS) plus LPS (10 μg/ml) for 48 h 
and images acquired using Olympus BX51 microscope at indicated times. Quantitation of cell migration was 
performed by manual counting of cells in the wound using enlarged images.
Biochemical analyses. Tissues and cells were lysed in RIPA buffer. Lysates were centrifuged at 18,000 × g 
for 10 min and protein concentrations determined by bicinchoninic acid protein assay kit (Pierce Chemical). 
Proteins (30 μg for cell lysates and 60 μg for tissue lysates) were resolved by SDS-PAGE and transferred to PVDF 
membranes. Immunoblotting was performed as we previously described59, 60 using antibodies for pNF-κBp65 
(Ser536), NF-κBp65, pp38 (Thr180/Tyr182), p38, pJNK (Thr183/Tyr185), JNK, pShp2 (Tyr542) (all from Cell 
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Signaling), Shp2, pPERK (Thr980), PERK, peIF2α (Ser52), eIF2α, sXBP1, IRE1α, Nephrin, actin and tubu-
lin (all from Santa Cruz). Antibodies for pIRE1α (Ser724) and pNephrin (Tyr1176/Tyr1193) were purchased 
from Abcam. Proteins were visualized using HyGLO chemiluminescence HRP detection reagent (Denville 
Scientific), and pixel intensities of immuno-reactive bands were quantitated using FluorChem 9900 software 
(Alpha Innotech). Data for phosphorylated proteins were presented as phosphorylation level normalized to pro-
tein expression.
Total RNA was extracted from kidneys using TRIzol (Invitrogen) and cDNA generated using high-capacity 
cDNA Synthesis Kit (Applied Biosystems). mRNA levels were assessed using SYBR Green quantitative real-time 
PCR using SsoAdvanced Universal SYBR Green Supermix (iCycler, Bio-Rad). Relative gene expression was nor-
malized to Tata-box binding protein (Tbp) and quantitated using the 2−ΔΔCT method as we previously described61. 
Primers sequences are listed in Table 1.
Statistical analyses. Data were expressed as means + standard error of the mean (SEM). Statistical analyses 
were performed using an unpaired heteroscedastic two-tailed Student’s t-test for Fig. 1a and one-way ANOVA 
tests for the other experiments. Differences were considered significant at p < 0.05.
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